Skip to content
10-K

Annual Report

OnKure Therapeutics, Inc. OKUR

0001193125-26-104147

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 11, 2026 13.67M sh
Shares Diluted FY 2025 · Dec 31, 2025 13.52M sh
Shares Diluted FY 2025 · Dec 31, 2024 3.45M sh
Capex FY 2025 · Dec 31, 2025 $46K
Capex FY 2025 · Dec 31, 2024 $52K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$51.83M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$51.12M
Cash And Equivalents FY 2025 · Dec 31, 2025 $59.05M
Cash And Equivalents FY 2025 · Dec 31, 2024 $110.76M
Stockholders Equity FY 2025 · Dec 31, 2025 $56.18M
Stockholders Equity FY 2025 · Dec 31, 2024 $103.83M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$101.84M
Current Liabilities FY 2025 · Dec 31, 2025 $5.92M
Current Liabilities FY 2025 · Dec 31, 2024 $10.53M
Total Liabilities FY 2025 · Dec 31, 2025 $5.93M
Total Liabilities FY 2025 · Dec 31, 2024 $11.08M
Current Assets FY 2025 · Dec 31, 2025 $60.84M
Current Assets FY 2025 · Dec 31, 2024 $113M
Total Assets FY 2025 · Dec 31, 2025 $62.12M
Total Assets FY 2025 · Dec 31, 2024 $114.91M
Eps Diluted FY 2025 · Dec 31, 2025 −$4.40
Eps Diluted FY 2025 · Dec 31, 2024 −$15.28
Eps Basic FY 2025 · Dec 31, 2025 −$4.40
Eps Basic FY 2025 · Dec 31, 2024 −$15.28
Sga Expense FY 2025 · Dec 31, 2025 $14.69M
Sga Expense FY 2025 · Dec 31, 2024 $10.59M
Rd Expense FY 2025 · Dec 31, 2025 $48.26M
Rd Expense FY 2025 · Dec 31, 2024 $43.8M
Net Income FY 2025 · Dec 31, 2025 −$59.52M
Net Income FY 2025 · Dec 31, 2024 −$52.67M
Operating Income FY 2025 · Dec 31, 2025 −$62.95M
Operating Income FY 2025 · Dec 31, 2024 −$54.39M